Growth HormoneResearch
IGF-1 DES
Also known as: DES IGF-1 · Des(1-3) IGF-1
A truncated IGF-1 variant with enhanced receptor binding affinity due to removal of the first three amino acids.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~20–30 minutes
Typical Dose
50–100 mcg
Administration
Subcutaneous or intramuscular injection
Mechanism of Action
Binds IGF-1 receptors with higher affinity than native IGF-1 due to reduced IGFBP binding, producing potent anabolic effects.
Key Research Areas
growth factormuscleIGF-1truncated
Frequently Asked Questions
What is IGF-1 DES?▾
A truncated IGF-1 variant with enhanced receptor binding affinity due to removal of the first three amino acids.
How does IGF-1 DES work?▾
Binds IGF-1 receptors with higher affinity than native IGF-1 due to reduced IGFBP binding, producing potent anabolic effects.
What is the recommended dosage for IGF-1 DES?▾
The typical research dosage is 50–100 mcg, administered via Subcutaneous or intramuscular injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of IGF-1 DES?▾
The half-life of IGF-1 DES is approximately ~20–30 minutes. This affects dosing frequency and timing in research protocols.
Is IGF-1 DES FDA approved?▾
IGF-1 DES is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about IGF-1 DES is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.